Advertisement

Pharmacological and invasive therapy for acute myocardial infarction

  • Rolf Schröder
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 170)

Abstract

Acute myocardial infarction secondary to atherosclerotic coronary artery disease is a leading cause of death in developed countries of the Western hemisphere. New dimensions and perspectives of clinical interest have emerged since acute coronary angiography ‘rediscovered’ the presence of a thrombus, usually superimposed on an atheromatous plaque, as the responsible culprit for the occlusion of an infarct-related artery. The observation that streptokinase infusion results in recanalization of occluded coronary arteries provided the basis for the development of thrombolytic therapy in patients with acute myocardial infarction.

Keywords

Acute Myocardial Infarction Acute Myocardial Infarction Thrombolytic Therapy Intravenous Streptokinase Suspected Acute Myocardial Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fibrinolytic Therapy Trialists’ (FIT) Collaborative group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1,000 patients. Lancet 1994; 343: 311–22.Google Scholar
  2. 2.
    GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; i: 397–401.Google Scholar
  3. 3.
    ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction: mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314: 1465–71.CrossRefGoogle Scholar
  4. 4.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349–60.Google Scholar
  5. 5.
    Linderer T, Schröder R, Arntz R et al. Prehospital thrombolysis: Beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol 1993; 22: 1304–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Weaver WD, Cerqueira M, Hallstrom AP et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy. J Am Med Assoc 1993; 270:1211–6.CrossRefGoogle Scholar
  7. 7.
    The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71–5.CrossRefGoogle Scholar
  8. 8.
    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group: ISIS-3. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–70.CrossRefGoogle Scholar
  9. 9.
    Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566–9.PubMedCrossRefGoogle Scholar
  10. 10.
    The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82.CrossRefGoogle Scholar
  11. 11.
    Ridker PM, O’Donnell C, Marder VJ, Hennekens CH. Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3 and GUSTO-1. Ann Intern Med 1993; 119: 530–2.PubMedGoogle Scholar
  12. 12.
    Anderson JL, Karagounis LA. Does intravenous heparin or time-to-treatment reperfusion explain differences between GUSTO and ISIS-3 results? Am J Cardiol 1994; 74: 1057–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Simoons ML, Arnold AER. Tailored thrombolytic therapy. Circulation 1993; 88: 2556–64.PubMedGoogle Scholar
  14. 14.
    Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Circulation 1993; 88: 296–306.PubMedGoogle Scholar
  15. 15.
    Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thrombosis Thrombolysis 1994; 1: 27–34.CrossRefGoogle Scholar
  16. 16.
    Reimer KA, Vander Heide RS, Richard VJ. Reperfusion in acute myocardial infarction: Effect of timing and modulating factors in experimental models. Am J Cardiol 1993; 72:13G–21G.PubMedCrossRefGoogle Scholar
  17. 17.
    LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759–66.CrossRefGoogle Scholar
  18. 18.
    Simoons ML, Serruys PW, van den Brand M et al. Early thrombolysis in acute myocardial infarction limitation of infarct size and improved survival. J Am Coll Cardiol 1986; 7: 717–28.PubMedCrossRefGoogle Scholar
  19. 19.
    Schröder R. Mechanisms by which thrombolysis reduces mortality: Limitation of infarct size — what else? In Sleight P, Chamberlain DA (eds): Thrombolysis: The Dawn of a New Era? London: IBC Technical Services Ltd 1990: 46–59.Google Scholar
  20. 20.
    Schröder R, Neuhaus KL, Linderer T, Brüggemann T, Tebbe U, Wegscheider K. Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (Results from the ISAM Study). Am J Cardiol 1989; 64: 878–84.PubMedCrossRefGoogle Scholar
  21. 21.
    Ambrose JA. The open artery: Beyond myocardial salvage. Am J Cardiol 1993; 72: 85G–90G.PubMedCrossRefGoogle Scholar
  22. 22.
    Hillis LD. The “open artery hypothesis” in survivors of myocardial infarction. ACC Current J Review 1993; Sept/Oct: 29–30.Google Scholar
  23. 23.
    Popovic AD, Neskovic AN, Babic et al. Independent impact of thrombolytic therapy and vessel patency on left ventricular dilation after myocardial infarction. Circulation 1994; 90: 800–7.PubMedGoogle Scholar
  24. 24.
    Simoons ML, Vos J, Tijssen JGP et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989; 14: 1609–15.PubMedCrossRefGoogle Scholar
  25. 25.
    Schröder R, Dissmann R, Brüggemann T et al. Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24: 384–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 1994; 74: 1220–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Vogt A, von Essen R, Tebbe U, Feuerer W, Appel KF, Neuhaus KL. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21: 1391–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Ohman EM, Califf RM, Topol EJ et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781–91.PubMedCrossRefGoogle Scholar
  29. 29.
    Meijer A, Verheugt FWA, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ. Aspirin versus Coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study. Circulation 1993; 87: 1524–30.PubMedGoogle Scholar
  30. 30.
    Meijer A, Verheugt FWA, van Eenige MJ, Werter CJ. Left ventricular function at 3 months after successful thrombolysis. Circulation 1994; 90: 1706–14.PubMedGoogle Scholar
  31. 31.
    Simoons ML, Arnold AER, Betriu A et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction; no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; 1: 197–203.PubMedCrossRefGoogle Scholar
  32. 32.
    The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction: TIMI II A results. J Am Med Assoc 1988; 260: 2849–58.CrossRefGoogle Scholar
  33. 33.
    Topol EJ, Califf RM, George BS et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Müller DWM, Topol EJ. Thrombolytic therapy: Adjuvant mechanical intervention for acute myocardial infarction. Am J Cardiol 1992; 69: 60A–70A.PubMedCrossRefGoogle Scholar
  35. 35.
    Schröder R, Vöhringer H, Linderer T, Biamino G, Brüggemann T, von Leitner ER. Follow-up after coronary arterial reperfusion with intravenous streptokinase in relation to residual myocardial infarct artery narrowings. Am J Cardiol 1985; 55: 313–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Ellis SG, Ribeiro da Silva E, Heyndrickx G et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994; 90: 2280–4.PubMedGoogle Scholar
  37. 37.
    Terrin ML, Williams DO, Kleiman NS et al. Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Clinical Trial. J Am Coll Cardiol 1993; 22: 1763–72.PubMedCrossRefGoogle Scholar
  38. 38.
    SWIFT Trial Study Group. SWIFT trial of delayed elective intervention vs conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. Br Med J 1991; 302: 555–60.CrossRefGoogle Scholar
  39. 39.
    Ellis SG, Mooney MR, George BS et al. Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Circulation 1992; 86: 1400–6.PubMedGoogle Scholar
  40. 40.
    Task Force on Myocardial Reperfusion. Reperfusion in acute myocardial infarction. Circulation 1994; 90: 2091–102.Google Scholar
  41. 41.
    Ellis SG, van de Werf F, Ribeiro da Silva E, Topol EJ. Present status of rescue coronary angioplasty: Current polarization of opinion and randomized trials. J Am Coll Cardiol 1992; 19: 681–6.PubMedCrossRefGoogle Scholar
  42. 42.
    McKendall GR, Forman S, Sopko G, Braunwald E, Williams DO, and the TIMI investigators. The value of rescue PTCA following unsuccessful thrombolytic therapy: A report from TIMI. J Am Coll Cardiol 1993; 21: 396A (Abstract).Google Scholar
  43. 43.
    Rogers WJ, Babb JD, Bairn DS et al. Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. J Am Coll Cardiol 1991; 17: 1007–16.PubMedCrossRefGoogle Scholar
  44. 44.
    Arnold AER, Simoons ML, Detry JM et al. Prediction of mortality following hospital discharge after thrombolysis for acute myocardial infarction: Is there a need for coronary angiography? Eur Heart J 1993; 14: 306–15.PubMedCrossRefGoogle Scholar
  45. 45.
    Linderer T, Guhl B, Spielberg Ch, Wunderlich W, Schnitzer L, Schröder R. Effect on global and regional left ventricular functions by percutaneous transluminal coronary angioplasty in the chronic stage after myocardial infarction. Am J Cardiol 1992; 69: 997–1002.PubMedCrossRefGoogle Scholar
  46. 46.
    Leung WH, Lau CP. Effects of severity of the residual stenosis of the infarct-related coronary artery on left ventricular dilation and function after acute myocardial infarction. J Am Coll Cardiol 1992; 20: 307–13.PubMedCrossRefGoogle Scholar
  47. 47.
    Dzavik V, Beanlands DS, Davies RF et al. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS] — A Pilot Study). Am J Cardiol 1994; 73: 856–61.PubMedCrossRefGoogle Scholar
  48. 48.
    O’Keefe JH, Bailey WL, Rutherford BD, Hartzler GO. Primary angioplasty for acute myocardial infarction in 1,000 consecutive patients. Am J Cardiol 1993; 72: 107G–15G.PubMedCrossRefGoogle Scholar
  49. 49.
    Roux S, Christeller S, Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: A meta-analysis. J Am Coll Cardiol 1992; 19: 671–77.PubMedCrossRefGoogle Scholar
  50. 50.
    Le Feuvre C, Yusuf S, Flather M, Farkouh M. Maximizing benefits of therapies in acute myocardial infarction. Am J Cardiol 1993; 72: 145G–55G.PubMedCrossRefGoogle Scholar
  51. 51.
    Ridker PM, Hebert PR, Fuster V, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? Lancet 1993; 341: 1574–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22.Google Scholar
  53. 53.
    ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral Captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995. In press.Google Scholar
  54. 54.
    Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Schäfer JH, Maurer A, Arntz HR et al. Akuter Myokardinfarkt: Aspekte der veränderten Sterblichkeit auf der Intensivstation. Dtsch med Wschr 1989; 114: 1143–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Naylor CD, Chen E. Population-wide mortality trends among patients hospitalized for acute myocardial infarction: The Ontario Experience, 1981 to 1991. J Am Coll Cardiol 1994; 24: 1431–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Rogers WJ, Bowlby LJ, Chandra NC et al. Treatment of myocardial infarction in the United States (1990 to 1993). Circulation 1994; 90: 2103–14.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Rolf Schröder

There are no affiliations available

Personalised recommendations